Teresa Lambe
Contact information
Research groups
D.PHIL PROJECTS
Teresa Lambe
Professor of Vaccinology & Immunology, Calleva Head of Vaccine Immunology
Honorary Officer of the Most Excellent Order of the British Empire (OBE), for services to Science and Public Health.
Vaccines are efficacious cost-effective healthcare measures and a global mainstay in protecting millions from infectious disease. We are particularly interested in delineating the immune response post vaccination and also post natural infection to help develop effective vaccines and also define correlates of protection. The establishment of protective immune responses following vaccination and the formation of adaptive immune memory are crucial for ensuring long-lived immunity toward infectious disease.
The Lambe group is currently developing and testing vaccines against a number of outbreak pathogens including Crimean-Congo haemorrhagic fever virus, Lassa virus, Nipah virus, Influenza, Ebolavirus and coronaviruses. A number of these vaccines have progressed to clinical trials, including the Oxford/AstraZeneca vaccine ChAdOx1 nCoV-19 against SARS-CoV-2 COVID-19 Vaccine Trials UK.
Recent publications
-
Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.
Journal article
O'Donnell KL. et al, (2024), International journal of molecular sciences, 25
-
Translational Science at the Undergraduate Level: Awakening Talents to Overcome the Valley of Death – Viewpoint Showing a Success Case (Preprint)
Preprint
Ferreira Jr RS. et al, (2024)
-
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Journal article
Costa Clemens SA. et al, (2024), The Lancet. Microbe
-
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Journal article
Flaxman A. et al, (2024), PLoS pathogens, 20
-
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.
Journal article
Bissett C. et al, (2024), NPJ vaccines, 9